Consultation record

Submissions accepted — page 22

The submission is accepted and the draft is amended as proposed. The amendment is recorded in the amendment log of the document it changed and is traceable to the numbered submission.

Submissions

681 documents · page 22 of 23

Table 1. Submissions with this disposition, on this page.

Reference	Consultation	Respondent	Point raised
DRAFT-BPC-157-HUMA/003	Draft synthesis: Human evidence for BPC-157	Sigrún Vercingetorix	Efficacy outcomes are rated for certainty and harms are not
DRAFT-BPC-157-HUMA/002	Draft synthesis: Human evidence for BPC-157	Dr Wilhelmina Oppenheimer-Ade	The same concept is given three different names in one document
DRAFT-BPC-157-HUMA/004	Draft synthesis: Human evidence for BPC-157	Dr Odalys Thorsby-Nakamura	The search date is not on the face of the document
DRAFT-GH-SECRETAGO/009	Draft synthesis: Clinical evidence for growth-hormone secretagogues…	Dr Gervase Abergavenny	The search strategy as published cannot be re-run
DRAFT-GH-SECRETAGO/008	Draft synthesis: Clinical evidence for growth-hormone secretagogues…	Dr Hyacinth Drakeford-Amadi	Results at materially different follow-up durations are pooled
DRAFT-GH-SECRETAGO/002	Draft synthesis: Clinical evidence for growth-hormone secretagogues…	Dr Zdenka Nyquist-Obiora	Overlapping primary studies across included reviews are counted more than once
DRAFT-GH-SECRETAGO/007	Draft synthesis: Clinical evidence for growth-hormone secretagogues…	Professor Bartolomeu Nkosi-Lindegaard	The review does not say when it will be updated or what would trigger an update
DRAFT-GH-SECRETAGO/001	Draft synthesis: Clinical evidence for growth-hormone secretagogues…	Dr Zofia Petrossian	Intention-to-treat and efficacy-estimand results are combined without distinction
DRAFT-GH-SECRETAGO/006	Draft synthesis: Clinical evidence for growth-hormone secretagogues…	Valentin Tollemache	Absence of evidence is presented in a form a reader will take as negative evidence
DRAFT-GH-SECRETAGO/005	Draft synthesis: Clinical evidence for growth-hormone secretagogues…	Gaspard Kettlewell	Analytical surveys are treated as evidence about suppliers when they establish only what was in a…
DRAFT-GH-SECRETAGO/003	Draft synthesis: Clinical evidence for growth-hormone secretagogues…	Dr Eulalia Sonnenberg-Eze	Studies using different outcome definitions are pooled into one estimate
DRAFT-RUSSIAN-REGI/012	Draft synthesis: Nationally registered neuropeptides and the…	Leonhard Achterberg	Registered trials that never reported are not counted anywhere in the review
DRAFT-RUSSIAN-REGI/007	Draft synthesis: Nationally registered neuropeptides and the…	Dr Melisande Kirkpatrick-Ola	An indirect comparison is presented without an assessment of transitivity
DRAFT-RUSSIAN-REGI/009	Draft synthesis: Nationally registered neuropeptides and the…	Dr Odalys Thorsby-Nakamura	A funnel plot is presented for a set too small to interpret it
DRAFT-RUSSIAN-REGI/001	Draft synthesis: Nationally registered neuropeptides and the…	Dr Gervase Abergavenny	Quantitative claims are reproduced without the method that produced them
DRAFT-RUSSIAN-REGI/003	Draft synthesis: Nationally registered neuropeptides and the…	Dr Beatrijs Hazelrigg	Analytical surveys are treated as evidence about suppliers when they establish only what was in a…
DRAFT-RUSSIAN-REGI/015	Draft synthesis: Nationally registered neuropeptides and the…	Xenia Nyquist-Obiora	Overlapping primary studies across included reviews are counted more than once
DRAFT-RUSSIAN-REGI/005	Draft synthesis: Nationally registered neuropeptides and the…	Hortensia Hollingworth	Intention-to-treat and efficacy-estimand results are combined without distinction
DRAFT-RUSSIAN-REGI/013	Draft synthesis: Nationally registered neuropeptides and the…	Vittoria Quintanilha	A single-trial result is presented in the visual form of a pooled estimate
DRAFT-SPONSOR-COND/005	Draft synthesis: The consequences of a wholly sponsor-generated…	Dr Odalys Thorsby-Nakamura	Results at materially different follow-up durations are pooled
DRAFT-SPONSOR-COND/007	Draft synthesis: The consequences of a wholly sponsor-generated…	Dr Piotr Hollingworth	The search strategy as published cannot be re-run
DRAFT-SPONSOR-COND/010	Draft synthesis: The consequences of a wholly sponsor-generated…	Dr Oisín Rautavaara industry	Two factual descriptions of the sponsor's programme are inaccurate
DRAFT-SURROGATE-OU/009	Draft synthesis: Percentage weight change as a surrogate outcome	Dr Jolyon Grünbaum-Sowande	Registered trials that never reported are not counted anywhere in the review
DRAFT-SURROGATE-OU/007	Draft synthesis: Percentage weight change as a surrogate outcome	Dr Lorcan Zaleski-Mbeki	Intention-to-treat and efficacy-estimand results are combined without distinction
DRAFT-SURROGATE-OU/003	Draft synthesis: Percentage weight change as a surrogate outcome	Dr Wolfram Kaltenbach-Mensah	The conclusion is stated more strongly than the certainty rating supports
DRAFT-SURROGATE-OU/005	Draft synthesis: Percentage weight change as a surrogate outcome	Dr Jacinta Steenkamp-Ferreira	Results at materially different follow-up durations are pooled
DRAFT-AMYLIN-ANALO/006	Draft synthesis: Amylin analogues as monotherapy and in combination	Dr Leonhard Quenneville	The conclusion is stated more strongly than the certainty rating supports
DRAFT-AMYLIN-ANALO/004	Draft synthesis: Amylin analogues as monotherapy and in combination	Xiomara Fairweather-Duru	Results at materially different follow-up durations are pooled
DRAFT-AMYLIN-ANALO/002	Draft synthesis: Amylin analogues as monotherapy and in combination	Dr Fenella Steenkamp-Ferreira	Intention-to-treat and efficacy-estimand results are combined without distinction
DRAFT-DISCONTINUED/003	Draft synthesis: Discontinued development programmes as evidence	Dr Liesbeth Delacroix-Njoku	The conclusion is stated more strongly than the certainty rating supports

page 22 of 23